Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPF 4778574
Description: Positive allosteric modulator of AMPA receptors
Chemical Name: N-[(3R,4S)-3-[4-(5-cyano-2-thienyl)phenyl]tetrahydro-2H-pyran-4-yl]-2-propanesulfonamide
Purity: ≥98% (HPLC)
Biological Activity for PF 4778574
Positive allosteric modulator of AMPA receptors (Ki = 85 nM). Prevents ketamine-induced working memory impairments. Brain penetrant.
Licensing Information
Sold for research purposes under agreement from Pfizer Inc.
Technical Data for PF 4778574
| M. Wt | 390.52 |
| Formula | C19H22N2O3S2 |
| Storage | Store at +4°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 1219633-99-4 |
| PubChem ID | 44462786 |
| InChI Key | FFAGHPLLBXWCSF-MSOLQXFVSA-N |
| Smiles | O=S(N[C@H]1CCOC[C@@H]1[C@]2=CC=C(C3=CC=C(C#N)S3)C=C2)(C(C)C)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for PF 4778574
References for PF 4778574
References are publications that support the biological activity of the product.
Roberts et al (2010) Prevention of KA-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction. Behav.Brain Res. 212 41 PMID: 20347881
Doran et al (2012) An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations. Drug Metab.Dispos. 40 2162 PMID: 22899853
Shaffer et al (2013) Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574. J.Pharmacol.Exp.Ther. 347 212 PMID: 23899905
View Related Products by Target
View Related Products by Product Action
Keywords: PF 4778574, PF 4778574 supplier, PF4778574, pam, positive, allosteric, modulators, potentiators, ampa, cognitive, enhancers, enhancement, brain, penetrant, bbb, AMPA, Receptors, 4900, Tocris Bioscience
Citations for PF 4778574
Citations are publications that use Tocris products.
Currently there are no citations for PF 4778574.
Reviews for PF 4778574
There are currently no reviews for this product. Be the first to review PF 4778574 and earn rewards!
Have you used PF 4778574?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.